Skip to main content

Table 1 Characteristics of the overall study population and stratification by HIV-1 DNA level at week 96

From: A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study

Variables Total (N = 69) Group 1 (N = 21) Group 2 (N = 48) P value
Sex     0.082
 Male 43 (62.3%) 10 (47.6%) 33 (68.8%)  
 Female 26 (37.7%) 11 (52.4%) 15 (31.2%)  
Age (years) 33 (27–39) 33 (29–41) 33 (27–38) 0.396
Time from diagnosis to ART (months) 7.7 (1.1–25.5) 6.0 (1.0–16.0) 9.0 (1.2–28.0) 0.556
HIV-1 subtype     0.422
 AE 21 (30.4%) 5 (23.8%) 16 (33.3%)  
 B/C/BC 19 (27.5%) 6 (28.6%) 13 (27.1%)  
 Not known 29 (42.1%) 10 (47.6%) 19 (39.6%)  
ART therapy     0.332
 AZT/d4T + 3TC + NVP 19 (27.5%) 7 (33.3%) 12 (25.0%)  
 TDF + 3TC + EFV 50 (72.5%) 14 (66.7%) 36 (75.0%)  
Pre-ART HIV-1 DNA
 (log10 copies/106 PBMCs), median (IQR),
2.0 (1.7–2.2) 1.8 (1.5–2.4) 2.0 (1.8–2.2) 0.379
Pre-ART plasma viral load
 (log10 copies/mL), median (IQR)
4.1 (3.6–4.5) 4.0 (3.6–4.4) 4.2 (3.7–4.6) 0.445
Pre-ART CD4+ T-cell count (cells/μL), median (IQR) 305 (256–385) 305 (274–412) 306 (232–378) 0.312
Nadir CD4+ T-cell count (cells/μL), median (IQR) 292 (245–357) 295 (271–374) 291 (224–350) 0.240
Pre-ART CD8+ T-cell count (cells/μL), median (IQR) 845 (614–1073) 859 (634–1114) 763 (607–1074) 0.907
Pre-ART CD4/CD8 ratio, median (IQR) 0.35 (0.27–0.51) 0.42 (0.29–0.51) 0.34 (0.24–0.49) 0.180
HIV-1 DNA after 2 years’ ART
(log10 copies/106 PBMCs), median (IQR)
1.7 (1.3–2.0) 1.3 (1.3–1.3) 1.9 (1.6–2.4) <0.001
  1. ART Antiretroviral therapy, PBMCs Peripheral blood mononuclear cells, IQR Inter-quartile range